This study demonstrates a robust and thorough trial design leading to accurate and objective data collection. We recommend that future studies investigating heavy menstrual bleeding (HMB) should follow, and improve upon, this rigorous approach to menstrual trial data collection, not only to validate clinical results but also to improve the techniques used to acquire these results. We propose that the state-of-the-art methodology described here be used as the basis for new guidelines for the implementation of clinical trials in the area of HMB.
FraserISCritchleyHOBroderMMunroMG. The FIGO Recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med. 2011;29(5):383–390.
3.
National Institute for Health and Clinical Excellence. Collaborating Centre for Women’s and Children’s Health. Heavy menstrual bleeding. http://guidance.nice.org.uk/CG44/Guidance/pdf/English. Accessed September 18, 2012.
4.
FraserISCritchleyHOMunroMGBroderM. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding?Hum Reprod. 2007;22(3):635–643.
5.
FraserISCritchleyHOMunroMGBroderM. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril. 2007;87(3):466–476.
6.
HallbergLHogdahlAMNilssonLRyboG.Menstrual blood loss--a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966;45(3):320–351.
7.
FraserISLanghamSUhl-HochgraeberK. Health-related quality of life and economic burden of abnormal uterine bleeding. Expert Rev Obstet Gynecol. 2009;4(2):179–189.
8.
JanssenCAScholtenPCHeintzAP. Reconsidering menorrhagia in gynecological practice. Is a 30-year-old definition still valid?Eur J Obstet Gynecol Reprod Biol. 1998;78(1):69–72.
9.
KadirRAAledortLM.Obstetrical and gynaecological bleeding: a common presenting symptom. Clin Lab Haematol. 2000;22(suppl 1):12–16; discussion 30-32.
10.
HurskainenRGrenmanSKomiIDiagnosis and treatment of menorrhagia. Acta Obstet Gynecol Scand. 2007;86(6):749–757.
11.
El-HemaidiIGharaibehAShehataH. Menorrhagia and bleeding disorders. Curr Opin Obstet Gynecol. 2007;19(6):513–520.
12.
JamesAHKouidesPAAbdul-KadirREvaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):124–134.
13.
KingROvertonC. Management of fibroids should be tailored to the patient. Practitioner. 2011;255(1738):19–23.
14.
MarjoribanksJLethabyAFarquharC.Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2006;(2):CD003855.
15.
BeaumontHAugoodCDuckittKLethabyA.Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev. 2007;(3):CD001017.
16.
LethabyAAugoodCDuckittKFarquharC.Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2007;(4): CD000400.
17.
LethabyAFarquharCCookeI. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;(4): CD000249.
18.
LethabyAIrvineGCameronI.Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev. 2008;1: CD001016.
19.
LethabyACookeIReesM.Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005;4: CD002126.
20.
FraserISMcCarronG. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol. 1991;31(1):66–70.
21.
FarquharCBrownJ.Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev. 2009: CD000154.
22.
ShabaanMMZakherahMSEl-NasharSASayedGH. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception. 2010;83(1):48–54.
FraserIParkeSMellingerUMachlittASerraniMJensenJ. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2011;16(4):258–269.
26.
JensenJPMellingerUMachlittAFraserIS. Estradiol valerate/dienogest OC for heavy and/or prolonged menstrual bleeding: a pooled analysis. Poster presented at: 58th American College of Obstetricians and Gynecologists Annual Clinical Meeting; April 2010; San Francisco, CA.
27.
FraserISWarnerPMarantosPA. Estimating menstrual blood loss in women with normal and excessive menstrual fluid volume. Obstet Gynecol. 2001;98(5 Pt 1):806–814.
28.
ReesMCCederholm-WilliamsSATurnbullAC. Coagulation factors and fibrinolytic proteins in menstrual fluid collected from normal and menorrhagic women. Br J Obstet Gynaecol. 1985;92(11):1164–1168.
29.
BaldwinRMWhalleyPJPritchardJA.Measurements of menstrual blood loss. Am J Obstet Gynecol. 1961;81:739–742.
30.
HighamJMO'BrienPMShawRW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;97(8):734–739.
31.
van EijkerenMAScholtenPCChristiaensGCAlsbachGPHaspelsAA. The alkaline hematin method for measuring menstrual blood loss--a modification and its clinical use in menorrhagia. Eur J Obstet Gynecol Reprod Biol. 1986;22(5-6):345–351.
ShawSTAaronsonDEMoyerDL. Quantitation of menstrual blood loss - further evaluation of the alkaline hematin method. Contraception. 1972;5(6):497–513.
34.
MoharramNMEl AouadRAl BusaidySInternational collaborative assessment study of the AHD575 method for the measurement of blood haemoglobin. East Mediterr Health J. 2006;12(6):722–734.
35.
HeuckCCReinauerHWoodWG. The alkaline haematin detergent (AHD575) method for the determination of haemoglobin in blood--a candidate reference measurement procedure. Clin Lab. 2008;54(7-8):255–272.
36.
JensenJParkeSMellingerUMachlittAFraserI. Effective treatment of heavy menstrual bleeding with estradiol valerate. Obstet Gynecol. 2011;117(4):777–787.
37.
FraserISRömerTParkeS. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing oestradiol valerate and dienogest: a randomised, double-blind Phase III trial. Hum Reprod. 2011;26(10):2698–2708.
